AR and prostate carcinoma: In an AR‐positive model with minimal expression of the variant AR‐V7, combinations of MRT‐2359 and enzalutamide were more efficacious than the respective single‐agent treatments, which warrant clinical investigation of MRT‐2359 as a single agent or in combination with an AR antagonist in patients with prostate cancer.[109] Therefore, the subsequent clinical trial of MRT‐2359 will focus on prostate cancer.[110]